Abeona Therapeutics Inc (NASDAQ:ABEO) has been assigned a $14.00 price target by equities researchers at Maxim Group in a research note issued on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective would indicate a potential upside of 145.61% from the company’s previous close.

A number of other brokerages have also recently issued reports on ABEO. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Tuesday, January 31st. Rodman & Renshaw reiterated a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Abeona Therapeutics in a report on Tuesday, February 7th. HC Wainwright set a $20.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Monday, February 6th. Jefferies Group LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Abeona Therapeutics in a report on Friday, February 17th. Finally, Cantor Fitzgerald reiterated a “positive” rating and set a $21.00 price objective on shares of Abeona Therapeutics in a report on Friday, February 17th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $15.18.

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Shares of Abeona Therapeutics (NASDAQ:ABEO) traded down 3.39% during midday trading on Thursday, reaching $5.70. 125,675 shares of the company’s stock traded hands. The stock has a 50 day moving average of $5.51 and a 200-day moving average of $5.43. Abeona Therapeutics has a 12 month low of $2.31 and a 12 month high of $9.44. The stock’s market cap is $229.45 million.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.28 million. Abeona Therapeutics had a negative net margin of 2,029.60% and a negative return on equity of 26.65%. On average, equities research analysts forecast that Abeona Therapeutics will post ($0.62) EPS for the current fiscal year.

WARNING: “Abeona Therapeutics Inc (ABEO) PT Set at $14.00 by Maxim Group” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/05/25/abeona-therapeutics-inc-abeo-pt-set-at-14-00-by-maxim-group.html.

Several hedge funds and other institutional investors have recently modified their holdings of ABEO. Hikari Power Ltd acquired a new position in shares of Abeona Therapeutics during the first quarter worth about $150,000. Highbridge Capital Management LLC boosted its position in Abeona Therapeutics by 108.1% in the fourth quarter. Highbridge Capital Management LLC now owns 551,800 shares of the biopharmaceutical company’s stock valued at $2,676,000 after buying an additional 286,657 shares during the period. Opaleye Management Inc. boosted its position in Abeona Therapeutics by 300.0% in the fourth quarter. Opaleye Management Inc. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $1,940,000 after buying an additional 300,000 shares during the period. Perceptive Advisors LLC purchased a new position in Abeona Therapeutics during the fourth quarter valued at $4,085,000. Finally, Tudor Investment Corp Et Al purchased a new position in Abeona Therapeutics during the fourth quarter valued at $162,000. Hedge funds and other institutional investors own 17.79% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

12 Month Chart for NASDAQ:ABEO

Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.